Search for: "Clinical Data, Inc." Results 181 - 200 of 1,004
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
9 Jan 2020, 12:29 pm by Renae Lloyd
The research and development process for pharma companies often involves costly and lengthy clinical testing trials that yield specific data. [read post]
5 Jan 2024, 1:22 pm by Eugene Volokh
An excerpt from a long report and recommendation released Wednesday by Magistrate Judge Ona Wang (S.D.N.Y.) in Cassava Sciences, Inc. v. [read post]
1 Jul 2012, 6:07 pm
Vivus Inc. and Orexigen Therapeutics Inc. are reportedly also trying to get their own versions of diet pills approved. [read post]
1 Jul 2012, 6:07 pm
Vivus Inc. and Orexigen Therapeutics Inc. are reportedly also trying to get their own versions of diet pills approved. [read post]
21 Jul 2021, 12:44 pm by Jon L. Gelman
The distributors named in the complaint were McKesson Corporation, Cardinal Health Inc., Amerisource Bergen Drug Corporation, and Rochester Drug Cooperative Inc. [read post]
21 Feb 2013, 3:45 pm
  No other data from the clinical trials was disclosed. [read post]
11 Oct 2011, 11:48 am by Dave Wingate, Senior Life Care Planning
Additionally, up to 70 percent of caregivers suffer clinical levels of depression, experts say. [read post]
1 Mar 2010, 8:56 am by Green and Associates
The six purported clinics involved in the fraud were: Zigma Medical Care, Inc., Tender Loving Care Medical Center, Inc, Professional Medical Health, Inc., Metro Med Care, Inc., San Diego Medical & Rehab Center, Inc., and Eulogia's Diagnostic Medical Center, Inc. [read post]
30 Oct 2007, 3:44 pm
Scouring electronic logs of other clinic patients, Ms. [read post]
30 Mar 2020, 10:00 pm
District Court for the District of Nevada issued a decision in the case of Amarin Pharmaceuticals, Inc. v. [read post]
19 May 2015, 2:29 pm by David Jensen
It acquired California Stem Cell, Inc., in Irvine in April of 2014 for $124 million. [read post]
19 Oct 2006, 11:53 am
AstraZeneca also paid $50-million to AtheroGenics Inc. last year to license its atherosclerosis drug candidate AGI-1067, which is now in late-stage clinical trials, with promises of another $950-million if the drug wins regulatory approval. [read post]